3 recruiting. 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow this condition Literature Review of Venentoclax trials Research Report on Venentoclax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial Venetoclax in combination with fludarabine and melphalan, Fludarabine and Melphalan - Venentoclax, Myeloid Malignancies | Phase 3 | Recruiting | First Affiliated Hospital of Zhejiang University | 186 | 2026-03-01 | 2026-03-17 |
| Venetoclax Combined With Azacitidine for Consolidation Therapy in AML Ara-C Group, VEN/AZA condsolidation - Acute Myeloid Leukemia, Consolidation Therapy | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 216 | 2026-02-01 | 2026-08-06 |
| The Maintenance Treatment of "ITIVA" in AML Patients recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine - Acute Myeloid Leukemia, Maintenance Treatment | Not applicable | Recruiting | Henan Cancer Hospital | 130 | 2023-07-11 | 2024-02-13 |
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia (2) · Leukemia, Myeloid (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
Azacitidine (1) · Interleukin-2 (1) · Melphalan (1) · Thalidomide (1) · fludarabine (1) · venetoclax (1)
First Affiliated Hospital of Zhejiang University (1) · Henan Cancer Hospital (1) · The First Affiliated Hospital of Soochow University (1)
China (3)